Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309017651> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W4309017651 endingPage "vii168" @default.
- W4309017651 startingPage "vii168" @default.
- W4309017651 abstract "Abstract BACKGROUND After multiple recurrences in glioma patients, bevacizumab is frequently used as salvage therapy. In this group of patients, we evaluated the prognostic value of amino acid PET using O-(2-[18F]fluoroethyl)-L-tyrosine (FET) before initiation of bevacizumab. METHODS We retrospectively identified adult glioma patients at recurrence with (i) at least one or more previous recurrences, (ii) who were treated with bevacizumab, and (iii) who underwent FET PET imaging before bevacizumab initiation. Maximum and mean tumor-to-brain ratios (TBRmax, TBRmean), metabolic tumor volume (MTV), and dynamic parameters (i.e., time-to-peak, slope) were obtained from FET PET. Additionally, contrast-enhancing volumes on MRI were calculated. Threshold values of imaging parameters for evaluating the prognosis were established by ROC analyses using overall survival (OS) of ≥ 6 months as reference. The prognostic value of imaging parameters was subsequently evaluated using the log-rank test and multiple logistic regression analyses. RESULTS Twenty-eight patients (glioblastoma, 96%) with a median of 2 recurrences (range, 1-5) were eligible for data evaluation. The patients received a median number of 7 bevacizumab cycles (range, 1-27). The static FET PET parameter TBRmean was the best parameter (threshold, 2.1; AUC, 0.78; P=0.014) to identify patients with a significantly longer OS (8.2 vs. 4.9 months; P=0.044). In contrast, the MTV, contrast-enhancing volume, and dynamic FET PET parameters were not significant. TBRmean remained significant in multiple logistic regression analysis (P=0.031), indicating an independent predictor for OS. CONCLUSION Our data suggest that static FET PET allows identifying patients with longer OS before initiation of bevacizumab." @default.
- W4309017651 created "2022-11-20" @default.
- W4309017651 creator A5018453143 @default.
- W4309017651 creator A5020096568 @default.
- W4309017651 creator A5031985321 @default.
- W4309017651 creator A5036157197 @default.
- W4309017651 creator A5046936224 @default.
- W4309017651 creator A5048404962 @default.
- W4309017651 creator A5068493621 @default.
- W4309017651 creator A5068510584 @default.
- W4309017651 creator A5075153407 @default.
- W4309017651 creator A5080394149 @default.
- W4309017651 creator A5082460705 @default.
- W4309017651 creator A5091809961 @default.
- W4309017651 date "2022-11-01" @default.
- W4309017651 modified "2023-09-30" @default.
- W4309017651 title "NIMG-27. THE PROGNOSTIC VALUE OF FET PET IN PATIENTS WITH RECURRENT GLIOMA TREATED WITH BEVACIZUMAB" @default.
- W4309017651 doi "https://doi.org/10.1093/neuonc/noac209.645" @default.
- W4309017651 hasPublicationYear "2022" @default.
- W4309017651 type Work @default.
- W4309017651 citedByCount "0" @default.
- W4309017651 crossrefType "journal-article" @default.
- W4309017651 hasAuthorship W4309017651A5018453143 @default.
- W4309017651 hasAuthorship W4309017651A5020096568 @default.
- W4309017651 hasAuthorship W4309017651A5031985321 @default.
- W4309017651 hasAuthorship W4309017651A5036157197 @default.
- W4309017651 hasAuthorship W4309017651A5046936224 @default.
- W4309017651 hasAuthorship W4309017651A5048404962 @default.
- W4309017651 hasAuthorship W4309017651A5068493621 @default.
- W4309017651 hasAuthorship W4309017651A5068510584 @default.
- W4309017651 hasAuthorship W4309017651A5075153407 @default.
- W4309017651 hasAuthorship W4309017651A5080394149 @default.
- W4309017651 hasAuthorship W4309017651A5082460705 @default.
- W4309017651 hasAuthorship W4309017651A5091809961 @default.
- W4309017651 hasBestOaLocation W43090176511 @default.
- W4309017651 hasConcept C126322002 @default.
- W4309017651 hasConcept C143998085 @default.
- W4309017651 hasConcept C151956035 @default.
- W4309017651 hasConcept C2776694085 @default.
- W4309017651 hasConcept C2777802072 @default.
- W4309017651 hasConcept C2778227246 @default.
- W4309017651 hasConcept C2780387249 @default.
- W4309017651 hasConcept C2989005 @default.
- W4309017651 hasConcept C502942594 @default.
- W4309017651 hasConcept C509974204 @default.
- W4309017651 hasConcept C71924100 @default.
- W4309017651 hasConceptScore W4309017651C126322002 @default.
- W4309017651 hasConceptScore W4309017651C143998085 @default.
- W4309017651 hasConceptScore W4309017651C151956035 @default.
- W4309017651 hasConceptScore W4309017651C2776694085 @default.
- W4309017651 hasConceptScore W4309017651C2777802072 @default.
- W4309017651 hasConceptScore W4309017651C2778227246 @default.
- W4309017651 hasConceptScore W4309017651C2780387249 @default.
- W4309017651 hasConceptScore W4309017651C2989005 @default.
- W4309017651 hasConceptScore W4309017651C502942594 @default.
- W4309017651 hasConceptScore W4309017651C509974204 @default.
- W4309017651 hasConceptScore W4309017651C71924100 @default.
- W4309017651 hasIssue "Supplement_7" @default.
- W4309017651 hasLocation W43090176511 @default.
- W4309017651 hasOpenAccess W4309017651 @default.
- W4309017651 hasPrimaryLocation W43090176511 @default.
- W4309017651 hasRelatedWork W1888656932 @default.
- W4309017651 hasRelatedWork W2062347107 @default.
- W4309017651 hasRelatedWork W2084397697 @default.
- W4309017651 hasRelatedWork W2157808018 @default.
- W4309017651 hasRelatedWork W2255997344 @default.
- W4309017651 hasRelatedWork W2462822954 @default.
- W4309017651 hasRelatedWork W2470588482 @default.
- W4309017651 hasRelatedWork W2742864767 @default.
- W4309017651 hasRelatedWork W2789731973 @default.
- W4309017651 hasRelatedWork W3200461578 @default.
- W4309017651 hasVolume "24" @default.
- W4309017651 isParatext "false" @default.
- W4309017651 isRetracted "false" @default.
- W4309017651 workType "article" @default.